JP2023548858A - Ｆｃｒｎ抗体及びその使用方法 - Google Patents

Ｆｃｒｎ抗体及びその使用方法 Download PDF

Info

Publication number
JP2023548858A
JP2023548858A JP2023526977A JP2023526977A JP2023548858A JP 2023548858 A JP2023548858 A JP 2023548858A JP 2023526977 A JP2023526977 A JP 2023526977A JP 2023526977 A JP2023526977 A JP 2023526977A JP 2023548858 A JP2023548858 A JP 2023548858A
Authority
JP
Japan
Prior art keywords
administration
seq
antibody
baseline
fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526977A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022098955A5 (https=
JP2023548858A5 (https=
Inventor
ラムチャンドラン，シンドゥ
サン，ホン
デニー，ウィリアム
アロヨ，サンティアゴ
イー． リン，レオナ
エイチ． リュー，ジョセリン
ジン，ジャンフア
ジョウヴァン，マリー－ヘレン
カーチャー，キース
ブラック，シャウン
チュー，ヤオウェイ
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2023548858A publication Critical patent/JP2023548858A/ja
Publication of JPWO2022098955A5 publication Critical patent/JPWO2022098955A5/ja
Publication of JP2023548858A5 publication Critical patent/JP2023548858A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023526977A 2020-11-06 2021-11-05 Ｆｃｒｎ抗体及びその使用方法 Pending JP2023548858A (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202063110884P 2020-11-06 2020-11-06
US63/110,884 2020-11-06
US202163137972P 2021-01-15 2021-01-15
US63/137,972 2021-01-15
US202163173126P 2021-04-09 2021-04-09
US63/173,126 2021-04-09
US202163173919P 2021-04-12 2021-04-12
US63/173,919 2021-04-12
US202163174423P 2021-04-13 2021-04-13
US63/174,423 2021-04-13
US202163175440P 2021-04-15 2021-04-15
US63/175,440 2021-04-15
US202163203075P 2021-07-07 2021-07-07
US202163219155P 2021-07-07 2021-07-07
US202163203077P 2021-07-07 2021-07-07
US63/203,077 2021-07-07
US63/203,075 2021-07-07
US63/219,155 2021-07-07
PCT/US2021/058188 WO2022098955A1 (en) 2020-11-06 2021-11-05 Fcrn antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023548858A true JP2023548858A (ja) 2023-11-21
JPWO2022098955A5 JPWO2022098955A5 (https=) 2024-11-14
JP2023548858A5 JP2023548858A5 (https=) 2024-11-14

Family

ID=81455198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526977A Pending JP2023548858A (ja) 2020-11-06 2021-11-05 Ｆｃｒｎ抗体及びその使用方法

Country Status (12)

Country Link
US (1) US20220144946A1 (https=)
EP (1) EP4240417A4 (https=)
JP (1) JP2023548858A (https=)
KR (1) KR20230117575A (https=)
AU (1) AU2021376364A1 (https=)
CA (1) CA3200972A1 (https=)
IL (1) IL302516A (https=)
JO (1) JOP20230098A1 (https=)
MX (1) MX2023005313A (https=)
PH (1) PH12023551241A1 (https=)
TW (1) TW202233236A (https=)
WO (1) WO2022098955A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
KR102921210B1 (ko) 2018-07-20 2026-01-30 모멘타 파머슈티컬스 인코포레이티드 Fcrn 항체 조성물
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
EP4615481A1 (en) * 2022-11-07 2025-09-17 argenx BV Methods for treating lupus nephritis using fcrn antagonists
WO2024163894A1 (en) * 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
TW202527982A (zh) * 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025163617A1 (en) * 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) * 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
WO2019118791A1 (en) * 2017-12-13 2019-06-20 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2020023310A1 (en) * 2018-07-20 2020-01-30 Williams Eva Compositions of fcrn antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250052465A (ko) * 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
CA3038894A1 (en) * 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
MA53903A (fr) * 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
EP4007605A4 (en) * 2019-08-01 2023-08-16 Momenta Pharmaceuticals, Inc. ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019110823A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
WO2019118791A1 (en) * 2017-12-13 2019-06-20 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2020023310A1 (en) * 2018-07-20 2020-01-30 Williams Eva Compositions of fcrn antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LING, L. E. ET AL.: "M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of", CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 105, no. 4, JPN6025044684, 2019, pages 1031 - 1039, ISSN: 0005812990 *

Also Published As

Publication number Publication date
KR20230117575A (ko) 2023-08-08
CA3200972A1 (en) 2022-05-12
TW202233236A (zh) 2022-09-01
IL302516A (en) 2023-07-01
AU2021376364A9 (en) 2024-09-12
EP4240417A1 (en) 2023-09-13
MX2023005313A (es) 2023-07-11
JOP20230098A1 (ar) 2023-05-04
PH12023551241A1 (en) 2023-11-20
AU2021376364A1 (en) 2023-06-22
WO2022098955A1 (en) 2022-05-12
US20220144946A1 (en) 2022-05-12
EP4240417A4 (en) 2024-10-02
WO2022098955A9 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
US20220144946A1 (en) Fcrn antibodies and methods of use thereof
JP7442575B2 (ja) Ｆｃｒｎ抗体及びその使用方法
US20220259308A1 (en) Fcrn antibodies and methods of use thereof
JP7420720B2 (ja) ＦｃＲｎ抗体およびその使用方法
US20220041694A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
EA051865B1 (ru) Антитела к fcrn и способы их применения
CN116782939A (zh) FcRn抗体及其使用方法
EA050428B1 (ru) АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40072884A (en) Fcrn antibodies and methods of use thereof
HK40104376A (en) Fcrn antibodies and methods of use thereof
BR122025025099A2 (pt) Anticorpos contra fcrn, usos dos mesmos e composições
HK40002836B (en) Fcrn antibodies and methods of use thereof
HK40002836A (en) Fcrn antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260310